title: Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.
abstract: The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
authors: Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA. becke021@mc.duke.edu
authors: Richard C
authors: RC
authors: Becker
authors: James
authors: J
authors: Scheiman
authors: Harold L
authors: HL
authors: Dauerman
authors: Frederick
authors: F
authors: Spencer
authors: Sunil
authors: S
authors: Rao
authors: Marc
authors: M
authors: Sabatine
authors: David A
authors: DA
authors: Johnson
authors: Frances
authors: F
authors: Chan
authors: Neena S
authors: NS
authors: Abraham
authors: Eamonn M M
authors: EM
authors: Quigley
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D012308:Risk Management; D015607:Stents / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D010975:Platelet Aggregation Inhibitors